COVAS-H 16/12.5mg price in UAE

Overview

Welcome to Dwaey, specifically on COVAS-H 16/12.5mg Tablets page.
This medicine contains an important and useful components, as it consists of Candesartan cilexetil, Hydrochlorothiazide.
COVAS-H 16/12.5mg is available in the market in concentration 16mg, 12.5mg/Tablet and in the form of Tablets.

OMAN PHARMACEUTICAL PRODUCTS is the producer of COVAS-H 16/12.5mg and it is imported from OMAN, The most popular alternatives of COVAS-H 16/12.5mg are listed downward .

Mode Of Action

Candesartan inhibits the binding of angiotensin II to AT1 receptors in many tissues (e.g. vascular smooth muscles, adrenal gland) which leads to vasoconstriction blockade and aldosterone release. Hydrochlorothiazide inhibits the reabsorption of Na and chloride in the distal tubules causing increased excretion of Na and water K and hydrogen ions.

Indication

Hypertension
Congestive heart failure

Precaution

Volume or sodium depletion, preexisting renal insufficiency; aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy, renal artery stenosis, primary hyperaldosteronism. Patients with a history of angioedema, urticaria. Monitor serum potassium levels especially in elderly and renally impaired patients. Hypotension may occur during major surgery and anaesthesia due to suppression of the renin-angiotensin system. Lactation: enters breast milk/contraindicated

Side Effects

1-10% Headache (3%)
Dizziness (3%)
Upper respiratory tract infection (4%)
Back pain (3%)
Flu-like syndrome (2%) Frequency Not Defined Candesartan Dizziness
headache
vertigo
back pain
upper resp tract infections
pharyngitis
rhinitis
hypotension
hyperkalaemia
increased serum creatinine. Hydrochlorothiazide Anorexia
Epigastric distress
Hypotension
Orthostatic hypotension
Photosensitivity
Anaphylaxis
Anemia
Confusion
Erythema multiforme
Stevens-Johnson syndrome
Exfoliative dermatitis including toxic epidermal necrolysis
Dizziness
Headache
Hyperuricemia
Hypokalemia and/or hypomagnesemia

Contra indication

Hypersensitivity.

Pregnancy and lactation

Pregnancy category: D

There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Pregnancy Category: C (1st trimester); D (2nd and 3rd trimesters)

Interaction

NSAIDs may reduce antihypertensive effect and result in deterioration of renal function including possible acute renal failure. May increase serum lithium concentration. K-sparing diuretics, K supplements or salt substitutes containing K may increase risk of hyperkalaemia. Potentially Fatal: Coadministration w/ aliskiren in diabetic patients may increase risk of renal impairment, hypotension and hyperkalaemia.